ASH 2023 | The use of azacitidine in HR-MDS and the potential of combination therapies
Sankalp Arora
• 9 Dec 2023
In this video, Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks on how azacitidine, a hypomethylating agent (HMA), is currently used in the treatment of patients with high-risk myelodysplastic syndromes (HR-MDS), and comments on the necessity for combination therapies in this space. Some doublet and triplet combinations are being investigated in these patients, and Dr Arora highlights that these will likely be crucial for patients who progress on HMAs.This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
